Indoco Remedies gets USFDA nod to Olanzapine Tablets to treat schizophrenia, bipolar disorder
Mumbai: Indoco Remedies has recently announced receipt of approval for its ANDA for Olanzapine Tablets USP 2.5mg, 5mg, 7.5 mg, 10mg, 15mg and 20 mg.The products are therapeutically equivalent to the Reference Listed Drug 'Zyprexa' of Eli Lilly.Olanzapine is indicated for the treatment of schizophrenia and bipolar disorder. The drug may also be used in combination with other medications to...
Mumbai: Indoco Remedies has recently announced receipt of approval for its ANDA for Olanzapine Tablets USP 2.5mg, 5mg, 7.5 mg, 10mg, 15mg and 20 mg.
The products are therapeutically equivalent to the Reference Listed Drug 'Zyprexa' of Eli Lilly.
Olanzapine is indicated for the treatment of schizophrenia and bipolar disorder. The drug may also be used in combination with other medications to treat depression and certain mental conditions.
The US market size of Olanzapine Tablets is USD 65 million as per available IMS data.
Commenting on this development, Ms. Aditi Kare Panandikar, Managing Director - Indoco Remedies Ltd. said, "The receipt of approval from the US health regulator to market the generic version of Olanzapine Tablets is very encouraging and will further supplement the solid dosage business for Indoco in the US."
Read also: Indoco Remedies Gets USFDA Nod For Succinylcholine Chloride Injection
Indoco Remedies Ltd., headquartered in Mumbai, is a fully integrated, research-oriented pharma Company with presence in 55 countries.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd